·   Log in

Archive for December 22nd, 2009

Contour USB

Instant info on blood sugar trends now possible by Contour USB glucose meter

Tuesday, December 22, 2009 19:32

Contour USB meter, a blood glucose monitor that connects directly to a PC or MAC - providing users with instant access to information and trends about their blood sugar levels - by Bayer is now available in markets.

This was posted under category: medical devices  |  Read Full Story  |  1 Comment
Tagged with: , ,

Teva recalls all lots of ketamine injection CIII 100mg/mL in 10mL vials for animal use in US

Tuesday, December 22, 2009 16:55

Teva Animal Health, Inc has expanded a nationwide voluntary recall of ketamine hydrochloride injection, in US due to adverse effects from the product.

This was posted under category: Consumer  |  Read Full Story  |  0 Comments
Tagged with:

Oversleeping pill Nuvigil’s (armodafinil) approval delayed in US: Cephalon

Tuesday, December 22, 2009 16:45

Pill to treat excessive sleepiness and improve wakefulness Nuvigil's (armodafinil) approval has been delayed by three months in US.

This was posted under category: Industry  |  Read Full Story  |  0 Comments
Tagged with: ,

Zegerid OTC pill to treat heartburn approved by US FDA

Tuesday, December 22, 2009 13:35

Zegerid, an over-the-counter pills to stop heart-burn or acidity in the stomach, has been approved by US FDA, announced Merck & Co, the producers of the drug.

This was posted under category: Consumer, health  |  Read Full Story  |  0 Comments
Tagged with: , ,

Oasis Infotech joins hands with Maventic to provide LIMS solutions for pharma, healthcare firms

Tuesday, December 22, 2009 13:20

Oasis Infotech, a developer of Laboratory Information Management System (LIMS) solutions, has joined hands with Maventic, Bangalore to accelerate production and supply management to pharma, healthcare and life science companies.

This was posted under category: medical devices  |  Read Full Story  |  0 Comments

Lenalidomide (Revlimid) extends disease-free survival in multiple myeloma patients: Study

Tuesday, December 22, 2009 4:43

Lenalidomide (Revlimid) extends disease-free survival in multiple myeloma patients: StudyLenalidomide (Revlimid) has been demonstrated its ability to considerably prolong disease-free survival in multiple myeloma patients.Lenalidomide (Revlimid) is a derivative of thalidomide. Results of a large randomized clinical trial for patients with multiple myeloma administered the oral drug lenalidomide appeared to have ...

This was posted under category: Clinical Trials  |  Read Full Story  |  0 Comments
Tagged with:

Diffuse large B-cell lymphoma drug pixantrone may get a quicker review in Europe

Tuesday, December 22, 2009 4:40

Diffuse large B-cell lymphoma drug pixantrone may get a quicker review in Europe Pixantrone, an investigational drug to treat diffuse large B-cell lymphoma (DLBCL), has been granted Orphan Drug status from European Medicines Agency (EMEA), Cell Therapeutics announced in a press release. Pixantrone (BBR 2778), is a novel topoisomerase II inhibitor with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. CTI expects to file the Marketing Authorization Application (MAA) in Europe for approval of pixantrone in mid-2010 and would be granted 10 year market exclusivity if it is approved. Pixantrone's New Drug Application (NDA) the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) will be reviewed by the US Food & Drug Administration's  Oncologic Drugs Advisory Committee (ODAC) on February 10, 2010. Pixantrone has received a fast track designation from US FDA as well and the product  has a prescription Drug User Fee Act (PDUFA) date of April 23, 2010. Orphan drug designation is granted in Europe for medical treatments and drugs intended to treat life-threatening or chronically debilitating conditions. Orphan drug designation enables pixantrone to get regulatory assistance, reduced regulatory fees associated with applying for marketing approval, and assistance with clinical trial design. "We will continue to work with the EMEA to move our application forward in Europe expeditiously as we prepare for potential commercial launch of pixantrone in the United States," stated Craig W. Philips, President of CTI. Diffuse large B-cell lymphoma (DLBCL) accounts for about 80% of aggressive non-Hodgkin's lymphoma. Headquartered in Seattle, CTI is a biopharmaceutical company developing an integrated portfolio of oncology products aimed at making cancer more treatable. Pixantrone, an investigational drug to treat diffuse large B-cell lymphoma (DLBCL), has been granted Orphan Drug status from European Medicines Agency (EMEA), Cell Therapeutics announced in a press release.

This was posted under category: Clinical Trials  |  Read Full Story  |  0 Comments
Tagged with: